A Green Sign – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
March 5, 2026
←
Previous Page
1
2